AbbVie’s upadacitinib successful in third late-stage dermatitis study

AbbVie (NYSE:ABBV) announces another successful Phase 3 clinical trial, AD Up, evaluating Rinvoq (upadacitinib) plus topical corticosteroids (TCS) in adults and adolescents with moderate-to-severe atopic dermatitis.

The trial met the co-primary endpoints and all secondary endpoints. Specifically, 77% of patients receiving 30 mg of upadacitinib plus TCS achieved EASI 75 (75% improvement in EASI score) compared to 26% in the placebo arm. 59% of patients in the cohort achieved clear or almost clear skin compared to 11% in the control arm. 64% experienced at least a four-grade improvement in itchy skin compared to 15% in the control arm.

Complete results will be submitted for presentation at a future medical conference and publication.

Two previous Phase 3s, MEASURE Up 1 & MEASURE Up 2, were also successful.

The FDA approved the JAK inhibitor for rheumatoid arthritis about a year ago.

https://seekingalpha.com/news/3595872-abbvies-upadacitinib-successful-in-third-late-stage-dermatitis-study